Aprea Therapeutics, Inc. cotiza a 0.59 USD y tiene una capitalización bursátil de $7M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is …
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.07 | $-0.22 | $-0.32 | $-0.47 |
| Estimado | $-0.22 | $-0.23 | $-0.36 | $-0.34 |
| Sorpresa | +68.2% | +4.3% | +11.1% | -38.2% |
| Métrica | APRE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -4631.1% | -38.6% | -4592.5% |
| Net Margin | -4409.2% | -33.6% | -4375.6% |
| FCF Margin | — | -13.9% | — |
| ROE | -101.3% | -40.4% | -60.9% |
| ROA | -79.1% | -32.0% | -47.1% |
| Current Ratio | 5.63 | 2.84 | +2.79 |
| Debt / Equity | — | 0.28 | — |